𝔖 Bobbio Scriptorium
✦   LIBER   ✦

An alternating chemotherapy combination (macoble) for intermediate and high-grade non-hodgkin's lymphoma

✍ Scribed by M. Harding; L. McNulty; J. Paul; F. Lee; D. Dunlop; M. Soukop

Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
485 KB
Volume
9
Category
Article
ISSN
0278-0232

No coin nor oath required. For personal study only.

✦ Synopsis

48 patients with intermediate or high-grade non-Hodgkin's lymphomas (NHL) received a CHOP based combination with the addition of etoposide on days 1 and 2, bleomycin days 1 and 10 and methotrexate 1.5 g/m2 on day 10 (MACOBLE). Their median age was 59 years, 20 (42 per cent) had an ECOG performance status (PS) of 2 or 3,24 (50 per cent) had stage IV disease, 25 (52 per cent) B symptoms and 21 (44 per cent) bulk (> 10 cm) disease.

With a median follow-up of 62 months, 12 patients are alive, 10 of whom arc disease-free. Median overall survival was 13 months (95 per cent confidence interval 6 2 3 months) with actuarial 5-year survival of 25 per cent (95 per cent confidence interval 13-37 per cent). Factors associated with inferior survival were ECOG PS 2 or 3 (P=0.004), B symptoms (P=0-013) and bulk disease (P=0.017).

These data suggest that, when treating an unselected patient population, attempts to increase the intensity of first-line chemotherapy may not improve the outcome.

πŸ“œ SIMILAR VOLUMES

Alternating chemotherapy regimen (P-VABE
Alternating chemotherapy regimen (P-VABEC) for intermediate and high-grade non-Hodgkin's lymphoma of the middle aged and elderly
✍ Dr. F. Caracciolo; M. Petrini; E. Capochiani; F. Papineschi; G. Carulli; B. Gras πŸ“‚ Article πŸ“… 1994 πŸ› John Wiley and Sons 🌐 English βš– 463 KB πŸ‘ 1 views

An intensive third generation regimen (P-VABEC) including adriamycin, etoposide, cyclophosphamide. vincristine, bleomycin and prednisolone was administered to 43 unselected elderly patients with intermediate or high-grade non-Hodgkin's lymphomas (NHL). The median age was 67, 40 per cent were Ann Arb

Sequential versus alternating chemothera
Sequential versus alternating chemotherapy for high grade non-hodgkin's lymphomas: A randomized multicentre trial
✍ H. KΓΆppler; K. H. PflΓΌger; I. Eschenbach; R. Pfab; J. Birkmann; W. Zeller; E. U. πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 406 KB

In a multicentre phase 111 trial 146 previously untreated patients with high grade non-Hodgkin's lymphomas stage I1 IV were randomized to receive either four cycles of CHOEP (cyclophosphamide 750 mg/m2 iv d 1, doxorubicin 50 mg/m2 iv d 1, vincristine 2 mg iv d 1, etoposide 100 mg/m2 iv d 3-5, predni

Long-term follow-up of patients receivin
Long-term follow-up of patients receiving salvage chemotherapy for intermediate and high grade non-Hodgkin's lymphomas
✍ Dr. Raymond H. S. Liang; Edmond K. W. Chiu; T. K. Chan; David Todd; Ronald P. Ng πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 423 KB πŸ‘ 1 views

This is an analysis of the long-term follow-up data of 99 patients receiving HOAP-Bleo, IMVP-16 and PAC as salvage chemotherapy for refractory or relapsed intermediate or high grade non-Hodgkin's lymphomas. Most of the patients received HOAP-Bleo or PAC following failure of initial chemotherapy and

Radiobiological characterization of two
Radiobiological characterization of two human chemotherapy-resistant intermediate grade non-Hodgkin's lymphoma cell lines
✍ Amr Aref; Razmi Mohammad; Mark Yudelev; Rajani Choudhuri; Amy Strowbridge; Colin πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 193 KB

Intermediate grade non-Hodgkin's lymphoma (IGNHL) is generally considered a radiosensitive tumor that can be controlled with moderate radiation doses. Cell-survival curves of cell lines derived from IGNHL have been typically described to exhibit small or no shoulder, implying inability to accumulate